The Food in addition to Drug Administration has cleared a mobile system that will could simplify diabetes management for some patients.
Doctors treating Type 2 diabetes patients with long-acting insulin usually prescribe them a daily dose to take, in addition to adjust the dose at follow-up visits based on how well the treatment can be working. Some doctors, mostly diabetes specialists, provide patients instructions on how the adjust the insulin dose between visits to bring blood sugar levels into an appropriate range.
Glooko’s Mobile Insulin Dosing System allows doctors to set a dosage in addition to pulls data coming from the patient’s glucose monitor to recalculate levels based on the reading. that will’s integrated into Glooko’s existing mobile app in addition to sends reminders to patients’ cellphones when that will’s time to take another dose.
“There’s an enormous unmet need for both [clinicians in addition to patients] — clinicians who aren’t comfortable with dosing in addition to therefore don’t put people on long-acting insulin,” said Glooko CEO Rick Altinger. “that will’s a wonderful drug if taken inside the right amount at the right time inside the right way. This particular overcomes a big need for clinicians in addition to saves them time. For patients, math can be hard.”
Altinger said the company decided to develop the system after learning some doctors in addition to patients struggle with manual calculations in addition to ensuring patients are following their treatment plan. The insight also came coming from analyzing data coming from Glooko’s existing diabetes management platform.
To test whether the system much better outcomes, Glooko conducted a study of 14 patients for between 7 in addition to 23 days. The system increased adherence to the treatment plan, which was related to positive outcomes, according to the results.
However, the study was conducted over a short period of time in addition to was not blind nor randomized, so that will’s possible that will some patients were more mindful of their diabetes management because they knew they were being tracked, said Dr. Tom Donner, director of the Johns Hopkins Comprehensive Diabetes Center.
Still, he believes the benefits were due to the app, since the subjects were prompted to boost their long-acting insulin dose, which he said doctors know will lower fasting glucose levels.
“If you had a device that will got somebody to their ultimate insulin dose more rapidly without causing low blood sugars, that will would certainly help speeding up getting somebody’s diabetes under control,” Donner said.
right now that will the system can be approved, Glooko will start commercializing that will in addition to work through reimbursement. One strategy could be to partner with pharmaceutical companies in addition to offer Glooko’s mobile insulin dosing system as a bundle with long-acting insulin products, Altinger said.
Michelle de Haaff, Glooko’s vice president of marketing in addition to customer success, said drugmakers could be interested because the system has the potential to keep patients on a particular brand.
“Once a clinician puts a patient on (a brand of long-acting insulin) in addition to something’s not right, they will change that will patient to another brand if that will seems like This particular brand can be not working,” she said. “that will’s a big frustration with pharmaceutical companies.”
She said all major long-acting insulin makers have shown interest. Glooko already incorporates a partnership with Novo Nordisk, which produces Levemir in addition to Tresiba. The two launched its Cornerstones4Care Powered by Glooko app last year.
In response to CNBC’s request for comment on Glooko’s brand-new system, a Novo Nordisk spokesman said the company “can be continuing to follow the development in addition to progress of This particular platform with great interest.”